BriaCell Therapeutics (TSX:BCT) Total Assets : C$16.42 Mil (As of Jan. 2024)

View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Total Assets?

BriaCell Therapeutics's Total Assets for the quarter that ended in Jan. 2024 was C$16.42 Mil.

During the past 12 months, BriaCell Therapeutics's average Total Assets Growth Rate was 805.90% per year. During the past 3 years, the average Total Assets Growth Rate was 126.00% per year. During the past 5 years, the average Total Assets Growth Rate was 64.30% per year.

During the past 13 years, BriaCell Therapeutics's highest 3-Year average Total Assets Growth Rate was 514.60%. The lowest was -86.80%. And the median was 126.00%.

Total Assets is connected with ROA %. BriaCell Therapeutics's annualized ROA % for the quarter that ended in Jan. 2024 was -289.14%. Total Assets is also linked to Revenue through Asset Turnover. BriaCell Therapeutics's Asset Turnover for the quarter that ended in Jan. 2024 was 0.00.

BriaCell Therapeutics Total Assets Historical Data

The historical data trend for BriaCell Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Total Assets Chart

BriaCell Therapeutics Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Total Assets

Get a 7-Day Free Trial

0.58

0.71

72.73

55.08

35.89

BriaCell Therapeutics Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Total Assets	Get a 7-Day Free Trial															45.85	40.08	35.89	25.53	16.42

BriaCell Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

BriaCell Therapeutics's Total Assets for the fiscal year that ended in Jul. 2023 is calculated as

Total Assets	=	Total Equity (A: Jul. 2023 )	+	Total Liabilities (A: Jul. 2023 )
	=	-4.99	+	40.876
	=	35.89

BriaCell Therapeutics's Total Assets for the quarter that ended in Jan. 2024 is calculated as

Total Assets	=	Total Equity (Q: Jan. 2024 )	+	Total Liabilities (Q: Jan. 2024 )
	=	-11.164	+	27.583
	=	16.42

BriaCell Therapeutics (TSX:BCT) Total Assets Explanation

Total Assets is connected with ROA %.

BriaCell Therapeutics's annualized ROA % for the quarter that ended in Jan. 2024 is

ROA %	=	Net Income (Q: Jan. 2024 )	/	( (Total Assets (Q: Oct. 2023 )	+	Total Assets (Q: Jan. 2024 ))	/ count )
	=	-60.644	/	( (25.53	+	16.418)	/ 2 )
	=	-60.644	/	20.974
	=	-289.14 %

Note: The Net Income data used here is four times the quarterly (Jan. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

BriaCell Therapeutics's Asset Turnover for the quarter that ended in Jan. 2024 is

	Asset Turnover
=	Revenue (Q: Jan. 2024 )	/	( (Total Assets (Q: Oct. 2023 )	+	Total Assets (Q: Jan. 2024 ))	/ count )
=	0	/	( (25.53	+	16.418)	/ 2 )
=	0	/	20.974
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

BriaCell Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics (TSX:BCT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

BCTX:USA

Address

235 - 15th Street, Suite 300, West Vancouver, 3rd Floor, Bellevue Centre, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is an immuno-oncology-focused biotechnology company. The group develops targeted and safe approaches for the management of cancer. BriaCell is conducting a Phase I/IIa clinical trial of Bria-IMT in metastatic breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for the treatment of advance-stage breast cancer by matching the patient's HLA type.

BriaCell Therapeutics (TSX:BCT) Headlines

No Headlines